Grimes & Company, Inc. Regulus Therapeutics Inc. Call Options Transaction History
Grimes & Company, Inc.
- $3.22 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RGLS
# of Institutions
47Shares Held
36.4MCall Options Held
239KPut Options Held
12.6K-
Federated Hermes, Inc. Pittsburgh, PA12.9MShares$23 Million0.09% of portfolio
-
Vivo Capital, LLC Palo Alto, CA5MShares$8.95 Million1.93% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.68MShares$6.59 Million0.02% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.27MShares$5.85 Million0.31% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.88MShares$3.36 Million0.0% of portfolio
About Regulus Therapeutics Inc.
- Ticker RGLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,634,400
- Market Cap $26.2M
- Description
- Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...